Dec. 11, 2012
/PRNewswire/ -- NI Research has released the December issue of
which features a comprehensive review of pharmacotherapies for depression, with a particular focus upon the programs developing RAADs, rapid-acting antidepressants, an approach that springs from the reports of accelerated depression relief via the use of ketamine.
This 29-page issue includes:
An overview of the biology of depression and the implications of accelerated treatment effect for our understanding of depression and pathways for intervention.
A review of the many therapeutic strategies that are currently under development, with a special focus upon glutamatergic approaches, those which access the NMDA receptor and associated modulator components. These constitute the pathways for RAADs, where symptom relief may occur in hours, rather than weeks.
Among the programs reviewed, the leaders in the race for a RAAD include:
, whose Phase IIa data for IV GLYX-13 was just released. In spite of the fact that this was a
dose-ranging study in TRD patients, limited by the small cohort sizes for each of the active treatment groups, GLYX-13 exceeded expectations. Most importantly, none of the doses produced psychotomimetic effects in any patients. The pilot study now requires confirmation from the multiple-dose PhIIb trial underway.
Various Ketamine and Ketamine-combination drugs: These programs are hoping to skirt the risk of psychotomimesis via a variety of tactics. Programs in this vein are underway at JNJ/Addex, Lilly, AstraZeneca,
, and Mt. Sinai.
's IV AZD6765 has been tested more extensively than most of its competitors, but it is relatively slow to achieve therapeutic effect, and psychotomimetic concerns are not completely alleviated.
has an orally bioavailable version of GLYX-13, NRX-1074, approaching IND-readiness. If it emulates GLYX-13's impact and safety, NRX-1074 would widen the scope of Naurex's market across the full range of depression. In terms of other oral glutamatergic options, companies involved in this area include:
Bristol Myers Squibb, Lilly
' ALKS5461 program has the burden of its opioid legacy, which would almost certainly result in Schedule II placement, and what may be some initial euphoric/intoxicant effects.
Other depression programs of note include: